Metagenomi Stock Price, News & Analysis

Metagenomi (MGX) reported its Q1 2025 financial results and business updates. The company highlighted promising results from its hemophilia A program, demonstrating sustained Factor VIII activity at therapeutically relevant levels over a 19-month study in nonhuman primates. The study showed FVIII activity levels of 80%, 10%, and 32% in three test subjects, correlating with gene integration frequencies. The company maintains a strong financial position with $226.0 million in cash and equivalents, expected to fund operations into 2027. R&D expenses decreased to $25.1 million from $31.4 million in Q1 2024, while G&A expenses reduced to $6.8 million from $8.8 million. Metagenomi also published research in Nature Communications describing novel compact CRISPR-associated transposases (CAST) systems, showcasing their AI-driven metagenomics platform's capabilities.

Metagenomi (Nasdaq: MGX) has announced its participation in two major scientific meetings in May 2025. The company will deliver an oral presentation at TIDES USA 2025 (May 19-22) focusing on AI-guided metagenomic discovery of CRISPR systems for therapeutic genome editing. Additionally, Metagenomi will present three posters at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting (May 13-17), covering topics including in vivo genome editing, site-specific integration of therapeutic transgenes, and CNS gene knockdown via AAV delivery. All presentations will be accessible on the company's investor relations website.

Metagenomi (Nasdaq: MGX) reported its full year 2024 financial results and business updates. The company ended Q4 2024 with $248.3 million in cash and equivalents, providing runway into 2027. Key highlights include sustained Factor VIII activity in nonhuman primate study for hemophilia A program for over 16 months, and advancement of four Wave 1 Ionis targets to lead optimization.

Financial results show R&D expenses increased to $109.2 million in 2024 from $94.4 million in 2023, while G&A expenses rose to $32.0 million from $28.8 million. The company's pipeline achievements include declaring development candidate MGX-001 for hemophilia A, achieving in vivo proof-of-concept across three secreted protein targets, and demonstrating 95% protein knockdown in hypertension studies.

Looking ahead, Metagenomi plans to release final FVIII durability data in H1 2025, file IND submissions in 2026, and nominate 1-2 development candidates from Ionis collaboration programs in 2025.

Metagenomi (Nasdaq: MGX) has published groundbreaking research in Nature Communications showcasing its novel, compact CRISPR-associated transposase (CAST) system for large gene integration. The company's AI-driven metagenomics platform discovered a compact Cas12k CAST system capable of precisely integrating therapeutic genes into the human genome.

Key achievements include:

• Successfully integrated large, therapeutically relevant genes into human cells
• Developed a first-in-class 'all-in-one' mRNA delivery approach
• Demonstrated integration of multiple cargoes to a safe-harbor site in the human genome

This technology shows potential for treating complex genetic diseases such as Wilson's disease, cystic fibrosis, and Duchenne Muscular Dystrophy. The company expects additional advancements in their large gene integration technology in 2025.

Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced that CEO and founder Brian C. Thomas, PhD, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will also host one-on-one investor meetings during the conference.

Metagenomi leverages an AI-driven metagenomics platform to develop curative therapeutics. The company's comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems. By studying genetic material from natural environments, Metagenomi has unlocked four billion years of microbial evolution to discover novel editing tools capable of correcting genetic mutations throughout the genome.

A live webcast of the presentation will be available on the company's investor relations website, with a replay available for a time.

Metagenomi (Nasdaq: MGX) has provided updates on its therapeutic development programs and outlined key milestones for 2025-2026. The company reported significant progress in its MGX-001 hemophilia A program, achieving sustained Factor VIII activity in nonhuman primate studies over 16+ months. The company plans regulatory interactions in 2025 and IND/CTA submissions in 2026.

The company is advancing its secreted protein deficiencies program, expecting NHP proof-of-concept in 2025 and development candidate nomination in 2026. In collaboration with Ionis, Metagenomi is progressing on cardiometabolic programs, targeting one to two development candidate nominations in 2025.

Metagenomi has also advanced its technology platforms, including compact SMART nucleases and novel Adenine Base Editors. The company's cash runway is expected to support operations into 2027.

Metagenomi (Nasdaq: MGX) has announced the appointment of Eric Bjerkholt, MBA, to its Board of Directors, effective January 27, 2025. Bjerkholt, currently CFO of Mirum Pharmaceuticals, will serve on Metagenomi's Audit and Compensation committees.

Bjerkholt brings significant pharmaceutical industry experience, having served as CFO at several companies including Chinook Therapeutics (acquired by Novartis AG) and Aimmune Therapeutics (acquired by Nestle Health Science). At Sunesis Pharmaceuticals, he held multiple executive roles including Executive VP of Corporate Development and Finance. His background includes healthcare investment banking at J.P. Morgan and senior finance roles at various companies.

Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO and founder, Brian C. Thomas, PhD, will deliver a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT in San Francisco.

The presentation will be accessible through a live webcast on the investor section of Metagenomi's website at https://ir.metagenomi.co/. A replay option will be available for a time at the same web address. Metagenomi specializes in developing curative therapeutics using its proprietary gene editing toolbox.

Metagenomi (Nasdaq: MGX) presented data demonstrating the precision and safety of its gene editing tools at the Nature Conference: RNA at the Bench and Bedside IV. The company highlighted two key developments: MGX-001, their hemophilia A candidate using the MG29-1 nuclease, showed no identifiable off-target editing and no evidence of translocations in primary human hepatocytes. Additionally, their Adenine Base Editor (ABE) for ex vivo cell therapy demonstrated no detectable translocations and no significant genomic base composition differences in primary T-cells compared to unedited cells.